Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Grübler, MR; Zittermann, A; Verheyen, ND; Trummer, C; Theiler-Schwetz, V; Keppel, MH; Malle, O; Richtig, G; Gängler, S; Bischoff-Ferrari, H; Scharnagl, H; Meinitzer, A; März, W; Tomaschitz, A; Pilz, S.
Randomized trial of vitamin D versus placebo supplementation on markers of systemic inflammation in hypertensive patients.
Nutr Metab Cardiovasc Dis. 2021; 31(11):3202-3209
Doi: 10.1016/j.numecd.2021.07.028
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Grübler Martin
- Co-Autor*innen der Med Uni Graz
- Keppel Martin
- Malle Oliver
- März Winfried
- Meinitzer Andreas
- Pilz Stefan
- Richtig Georg
- Scharnagl Hubert
- Theiler-Schwetz Verena
- Tomaschitz Andreas
- Trummer Christian
- Verheyen Nicolas Dominik
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND AND AIMS: Animal and cell models indicated that vitamin D modulates inflammatory activity, which is considered relevant in the pathogenesis of arterial hypertension and cardiovascular diseases. We therefore aimed to investigate the effect of vitamin D supplementation on systemic markers of inflammation in a cohort of hypertensive patients. METHODS AND RESULTS: The Styrian Vitamin D Hypertension Trial is a single-centre, double-blind, placebo-controlled study conducted from 2011 to 2014 in Austria. We enrolled 200 study participants with arterial hypertension and 25-hydroxy-vitamin-D (25(OH)D) concentration below 30 ng/mL. Study participants were randomized to receive either 2800 IU of vitamin D3 per day or placebo for 8 weeks. The present investigation is a post-hoc analysis using analysis of co-variance (ANCOVA). Outcome measures were biomarkers of inflammation including CRP, leukocytes including subtypes and leukocyte-to-lymphocyte ratio, leucine and kynurenic acid. A total of 187 participants (mean age 60.1 ± 11.3years; 47% women; mean baseline 25(OH)D 21.1 ± 5.6 ng/mL) completed the trial. ANCOVA revealed a mean treatment effect for none of the respective outcomes and no significant results were detected in various subgroup analyses. CONCLUSION: Vitamin D3 supplementation in hypertensive patients with insufficient 25(OH)D concentrations has no significant effect on lowering markers of systemic inflammation. Further studies investigating the effect of vitamin D on other inflammatory pathways and in populations with severe vitamin D deficiency and a significant inflammatory burden are required. REGISTRATION: ClinicalTrials.gov Identifier: NCT02136771; EudraCT No. 2009-018,125-70. Start Date: 2011-04-06.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Austria - administration & dosage
- Biomarkers - blood
- Cholecalciferol - adverse effects, therapeutic use
- Dietary Supplements - adverse effects
- Double-Blind Method - administration & dosage
- Female - administration & dosage
- Humans - administration & dosage
- Hypertension - blood, diagnosis, drug therapy, immunology
- Inflammation Mediators - blood
- Male - administration & dosage
- Middle Aged - administration & dosage
- Time Factors - administration & dosage
- Treatment Outcome - administration & dosage
- Vitamin D - analogs & derivatives, blood
- Vitamin D Deficiency - blood, diagnosis, drug therapy
- Vitamins - adverse effects, therapeutic use
- Find related publications in this database (Keywords)
- Vitamin D
- Supplementation
- Inflammation
- Randomized controlled trial
- Hypertension